- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Rosalind Advisors Inc. Boosts Stake in CG Oncology
Hedge fund increases holdings in clinical-stage biotech company by over 55%
Mar. 13, 2026 at 10:52am
Got story updates? Submit your updates here. ›
Rosalind Advisors Inc., an investment management firm, has increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 55.5% in the third quarter, according to a recent SEC filing. The fund now owns 300,000 shares of the clinical-stage biopharmaceutical company, making it one of the top institutional investors in CG Oncology.
Why it matters
CG Oncology is a promising biotech company developing novel antibody-based immunotherapies for solid tumor cancers. The increased investment by Rosalind Advisors signals confidence in the company's pipeline and future growth potential, which could be a positive sign for other investors.
The details
According to the 13F filing, Rosalind Advisors Inc. added 107,026 shares of CG Oncology in the third quarter, bringing its total holdings to 300,000 shares. This represents approximately 0.39% of the company's outstanding shares and makes Rosalind Advisors one of the top 10 institutional investors in CG Oncology.
- Rosalind Advisors Inc. increased its stake in CG Oncology during the third quarter of 2026.
- CG Oncology's stock price has ranged from $14.80 to $64.67 over the past 52 weeks.
The players
Rosalind Advisors Inc.
An investment management firm that has increased its stake in the clinical-stage biotech company CG Oncology.
CG Oncology, Inc.
A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers.
The takeaway
The increased investment by Rosalind Advisors in CG Oncology suggests that the hedge fund sees significant growth potential in the biotech company's pipeline of cancer immunotherapies. This could be a positive sign for other investors interested in the promising field of antibody-based cancer treatments.
